Differences in growth parameters in SGA / IUGR children and patiens with growth hormone deficiency treated with recombinant growth hormone

In the Czech Republic is born to 5 % of SGA / IUGR children, about 5, 000 children a year, and their incidence is increasing. In 10 - 15 % does not occur postnatal compensation growth acceleration and growth retardation is then further deepens. Since 2003, these children can be treated by recombinant growth hormone in supraphysiological doses. Master thesis brings informations about SGA / IUGR children and their growth parameters during the first 2 years from the beginning of treatment when the monitoring was carried out at three - month intervals. The results are compared with the group of patients treated with growth hormone for growth hormone deficiency. Growth data was processed by a group of 57 SGA / IUGR children, which was compared with data of 34 children with growth hormone deficiency treated between 2003-2015 with growth hormone. Treatment of both groups of patients was carried out by a suitable therapeutic protocol, with the dose of GH by the respective diagnosis. These parameters were monitored: body height and weight, growth rate, BMI and weight - height ratio of patients. SGA / IUGR and GHD patients showed different growth profile in the initial phase of treatment when GHD patients had higher acceleration peak after 3 months of starting treatment and steeper increase in growth rate...